City
Epaper

Jaishankar welcomes WHO's decision to grant Emergency Use Listing to Covaxin

By ANI | Published: November 03, 2021 7:26 PM

External Affairs Minister Dr S Jaishankar on Wednesday welcomed the World Health Organisation (WHO)'s decision to grant approval for Emergency Use Listing (EUL) for Hyderabad-based Bharat Biotech's COVID-19 vaccine, Covaxin.

Open in App

External Affairs Minister Dr S Jaishankar on Wednesday welcomed the World Health Organisation (WHO)'s decision to grant approval for Emergency Use Listing (EUL) for Hyderabad-based Bharat Biotech's COVID-19 vaccine, Covaxin.

"Welcome @WHO's decision to grant Emergency Use Listing to #COVAXIN. It facilitates travel for many Indian citizens and contributes to vaccine equity. Also a global recognition to PM @narendramodi's vision of an #AtmanirbharBharat. A Happier Diwali," Jaishankar tweeted.

The World Health Organization (WHO) has issued an emergency use listing for India's indigenous vaccine Covaxin, adding to a growing portfolio of vaccines validated by WHO for prevention of COVID-19.

The WHO said in a tweet that the Technical Advisory Group, convened by World Health Organisation (WHO), has determined that the Hyderabad-based Bharat Biotech's COVID-19 vaccine meets WHO standards for protection against COVID-19.

"WHO has granted emergency use listing (EUL) to COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19," WHO said in a tweet.

"The Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that the Covaxin vaccine meets WHO standards for protection against #COVID19, that the benefit of the vaccine far outweighs risks and the vaccine can be used," it added.

The global health body said that the Covaxin vaccine was also reviewed by WHO's Strategic Advisory Group of Experts on Immunization (SAGE), and recommended the use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above.

"Available data on vaccination of pregnant women with the Covaxin vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry," WHO said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat Biotech InternationalDr s jaishankarWorld Health OrganisationBharat biotech limitedBharat biotech international ltdBharat biotech companyBharat biotech internationalBharat biotech biotech
Open in App

Related Stories

NationalCovaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine, Says ‘Safety Is Primary Focus for All Our Vaccines’

LifestyleWorld Health Day 2024: Date, Theme, History, Significance and Importance

MaharashtraMumbai: Yashwantrao Chavan Centre's National Award Announced to Dr. Soumya Swaminathan

International100% We Will Have 15 Years of Stable Government, Possibly Longer, Says EAM Dr S Jaishankar in Japan (Watch Video)

InternationalNon-Smokers Gain Ground: Global Tobacco Use Declines by 110 Million, New Gen Says No

International Realted Stories

InternationalIsrael Continues Attack on Gaza’s Jabalia Camp, Urges Civilian Evacuation

InternationalUS: Six killed, 10 injured in truck-van collision in Idaho

International10 Ukrainian drones suppressed in Russia's Krasnodar

InternationalSri Lanka: Seetha Amman Temple hosts grand Kumbaabhishekam puja with global devotee attendance

InternationalBalochistan Assembly demands medical college in Kharan district